OncoMatch/Clinical Trials/NCT06561347
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Is NCT06561347 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Zanubrutinib and Bendamustine for waldenstrom macroglobulinemia.
Treatment: Zanubrutinib · Bendamustine · Rituximab — The purpose of this study is to determine the very good partial response (VGPR) or better rate in participants with Waldenström macroglobulinemia (WM). The names of the study drugs involved in this study are as follows: zanubrutinib, bendamustine, and rituximab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Allowed: MYD88 L265P mutation
MYD88 L265P mutation plus CXCR4 wild type
Allowed: CXCR4 wild-type
MYD88 L265P mutation plus CXCR4 wild type
Allowed: MYD88 L265P mutation
MYD88 L265P mutation plus CXCR4 mutation
Allowed: CXCR4 mutation
MYD88 L265P mutation plus CXCR4 mutation
Allowed: MYD88 wild-type
MYD88 wild type
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Absolute neutrophil count ≥500/mcL believed to be caused by WM bone marrow involvement; Platelets ≥30,000/mcL believed to be caused by WM bone marrow involvement; Hemoglobin ≥ 7 g/dL
Kidney function
Creatinine clearance ≥30 mL/min using the Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 X institutional ULN, or ≤3 x institutional ULN with documented liver metastases and/or Gilbert's Disease; AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal, or ≤5 X institutional ULN with documented liver metastases
Participants must meet the following organ and marrow function as defined below: * Absolute neutrophil count ≥500/mcL believed to be caused by WM bone marrow involvement. Growth factors are not permitted <14 days prior to C1D1. * Platelets ≥30,000/mcL believed to be caused by WM bone marrow involvement. Platelet transfusions are not permitted <14 days prior to C1D1. * Hemoglobin ≥ 7 g/dL. RBC transfusions are not permitted <14 days prior to C1D1. * Total bilirubin ≤ 1.5 X institutional ULN, or ≤3 x institutional ULN with documented liver metastases and/or Gilbert's Disease * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal, or ≤5 X institutional ULN with documented liver metastases * Creatinine clearance ≥30 mL/min using the Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Colorado Blood Cancer Institute (CBCI) · Denver, Colorado
- Massachusetts General Hospital · Boston, Massachusetts
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
- University of Texas Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify